Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Novel Agent Perifosine enhances antitumor activity of Bortezomib and rituximab in Waldenstrom Macroglobulinemia

Novel Agent Perifosine enhances antitumor activity of Bortezomib and rituximab in Waldenstrom Macroglobulinemia. ASH. 2006.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.